StockTipsArenaBeta

BUY Mankind Pharma Limited — Shrikant Chouhan, Kotak Securities

BUYMankind Pharma Limited
Mankind Pharma share price target & all analyst calls

byShrikant Chouhan, Kotak SecuritiesHorizon: 1–3 months29 Sept 2026via CNBC Awaaz.

Entry₹2,545Inferred
Target₹2,650
Total upside +4.13% (call closed)
Stop lossNot given
Exit₹2,6509 Nov 2026, 9:24 am
Target hit+4.13%0.00%upside left
Follow Shrikant Chouhan for new calls(46% target hit, 37 closed calls)Get alertsWatch MANKIND for new buy/sell callsGet alertsSee 2 active Short-term calls on MANKINDSee 84 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 9 Nov 2026
16 supporting5 neutral3 opposing
Supports the BUY call (16)

Mankind Pharma shares jump 8% as Q2 profit rises 38% to Rs 716 crore

NewsEt-Markets·27 Oct · 2w ago

(opens in new tab)

Dr Reddy's stock could rise 10-15% if a major biosimilar gets approved in December: Systematix

NewsCnbc-Tv18·27 Oct · 2w ago

(opens in new tab)

Mankind Pharma jumps 8% on Q2 earnings beat but here's why analysts remain concerned

NewsCnbc-Tv18·27 Oct · 2w ago

(opens in new tab)

Mankind Pharma Shares Jump Nearly 8% After Q2 Profit Rises 39%

NewsNdtv-Profit·27 Oct · 2w ago

(opens in new tab)

6 advisors have active long-term BUY calls on this stock, with 5 issued in the last 14 days

Advisor consensus · adjacent horizon·27 Oct · 2w ago

Neutral / worth noting (5)

Mankind Pharma Q2 Review: Export Momentum Continues; Systematix Maintains 'Hold'; Check Target Price

NewsNdtv-Profit·27 Oct · 2w ago

(opens in new tab)

Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·26 Oct · 2w ago

(opens in new tab)
Weighs against the BUY call (3)

1 advisor has an active long-term SELL call on this stock

Advisor consensus · adjacent horizon·31 Jul · 3mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Mankind Pharma

All analyst calls on Mankind Pharma

More from Shrikant Chouhan, Kotak Securities

Every call and its outcome